Prostate cancer mortality in Connecticut, Iowa and New Mexico African American men

Cancer Detection and Prevention

Volumn 28, Issue 5, 2004, Pages 375-380

  Escobedo, Luis G ^a   Rivas, Saul D ^b   Holmes, Michelle D ^c  

^a Public Health Division   (Mexico)

^b NEW MEXICO STATE UNIVERSITY   (United States)

^c CHANNING LABORATORY   (United States)

Author keywords

African American; Incidence; Mass screening; Mortality; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AFRICAN AMERICAN; AGED; ARTICLE; COMPARATIVE STUDY; ETHNOLOGY; HUMAN; INCIDENCE; MALE; MIDDLE AGED; MORTALITY; PROSTATE TUMOR; STATISTICS; SURVIVAL RATE; UNITED STATES;

AFRICAN AMERICANS; AGED; CONNECTICUT; HUMANS; INCIDENCE; IOWA; MALE; MIDDLE AGED; NEW MEXICO; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 8144220849     PISSN: 0361090X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cdp.2004.06.003     Document Type: Article

References (40)

1. P.A. Wingo, C.J. Cardinez, and S.H. Landis Long-term trends in cancer mortality in the United States, 1930-1998 Cancer 97 Suppl. 12 2003 3133 3275
2. M.S. Eberhardt, D.D. Ingram, and D.M. Makuc Health, United States, 2001. Urban and Rural Health Chartbook 2001 National Center for Health Statistics Hyattsville (MD) [Table 55]
3. M.S. Eberhardt, D.D. Ingram, and D.M. Makuc Urban and Rural Health Chartbook. Health, United States, 2001 2001 National Center for Health Statistics Hyattsville (MD) [Table 30]
4. W.F. Gee, H.L. Hotgrewe, and M.L. Blute American urological association gallup survey: changes in diagnosis and management of prostate cancer and benign prostatic hyperplasia, and other practice trends from 1994 to 1997 J. Urol. 160 1998 1804 1807
5. R.G. Middleton, I.M. Thompson, and M.S. Austenfeld Prostate cancer clinical guidelines panel summary report on the management of clinically localized prostate cancer J. Urol. 154 1995 2144 2148
6. C.J. Mettlin, G.P. Murphy, D.S. Rosenthal, and H.R. Menck The national cancer data base report on prostate carcinoma after the peak in incidence rates in the U.S. Cancer 83 1998 1679 1684
7. B.F. Hankey, E.J. Feuer, and L.X. Clegg Cancer surveillance series: interpreting trends in prostate cancer - Part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates JNCI 91 1999 1017 1024
8. G.L. Lu-Yao, and E.R. Greenberg Changes in prostate cancer incidence and treatment in USA Lancet 343 1994 251 254
9. O.W. Brawley Prostate carcinoma incidence and patient mortality Cancer 80 1997 1857 1963
10. C.J. Mettlin, G.P. Murphy, J. Sylvester, R.F. McKee, M. Morrow, and D.P. Winchester Results of hospital cancer registry surveys by the American College of Surgeons: outcomes of prostate cancer treatment by radical prostatectomy Cancer 80 1997 1875 1881
11. A.L. Potosky, B.A. Miller, P.C. Albertsen, and B.S. Kramer The role of increasing detection in the rising incidence of prostate cancer JAMA 273 1995 548 552
12. J. Howard, B.F. Hankey, and R.S. Greenberg A collaborative study of differences in the survival rates of black patients and white patients with cancer Cancer 69 1992 2349 2360
13. C.J. Bradkey, C.W. Given, and C. Roberts Disparities in cancer diagnosis and survival Cancer 91 2001 178 188
14. C.J. McDonald The American Cancer Society addressing disparities and the disproportionate burden of cancer Cancer Suppl. 91 2001 195 198
15. L.A.G. Ries C.L. Kosary B.F. Hankey B.A. Miller L.X. Clegg B.K. Edwards SEER Cancer Statistics Review, 1973-1996: Tables and Graphs 1999 National Cancer Institute Bethesda (MD) 422 [NIH Pub. No. 99-2789]
16. J.E. Fowler Jr., and S.A. Bigler A prospective study of the serum prostate specific antigen concentrations and gleason histologic scores of Black and White men with prostate carcinoma Cancer 86 1999 836 841
17. A.S. Robbins, A.S. Whittenmore, and S.K. Van Den Eeden Race, prostate cancer survival, and membership in a large health maintenance organization JNCI 90 1998 986 990
18. C.J. Mettlin, G.P. Muphy, M.P. Cunningham, and H.R. Menck The national cancer data base report on race, age, and region variations in prostate cancer treatment Cancer 80 1997 1261 1266
19. L. Harlan, O. Brawley, F. Pommerenke, P. Wali, and B. Kramer Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate J. Clin. Oncol. 13 1995 93 100
20. W. Underwood, S. De Monner, P. Ubel, A. Fagerlin, M.G. Sanda, and J.T. Wei Racial/ethnic disparities in the treatment of localized/regional prostate cancer J. Urol. 171 2004 1504 1507
21. C.N. Klabunde, A.L. Potosky, L.C. Harlan, and B.S. Kramer Trends and black/white differences in treatment for nonmetastatic prostate cancer Med. Care 1998 1337 1348
22. National Cancer Institute. A Guide to Using SEER*Stat, version 3.0. Bethesda, Maryland.
23. J.R. Elliott Cycles within the system: metropolitanisation and internal migration in the US, 1965-90 Urban Stud. 34 1997 21 41
24. J.J. Guidry, L.A. Aday, D. Zhang, and R.J. Winn Cost considerations as potential barriers to cancer treatment Cancer Pract. 6 1998 182 187
25. N.E. Breslow, and N.E. Day Statistical methods in cancer research The design and analysis of cohort studies 59 1987 International Agency for Research on Cancer Lyon, France 59 [volume II]
26. K.J. Rothman, and S. Greenland Modern Epidemiology 2nd ed. 1998 Lippincott Williams & Wilkins Philadelphia
27. C.R. Smart The results of prostate carcinoma screening in the US as reflected in the surveillance, epidemiology, and end results program Cancer 80 1997 1835 1844
28. C.J. Mettlin, and G.P. Murphy Why is the prostate cancer death rate declining in the United States? Cancer 82 1998 249 251
29. C.H. Hennekens, and J.E. Buring Epidemiology in Medicine 1st ed. 1987 Little, Brown and Company Boston/Toronto
30. E.A. Jacobs, and D.S. Lauderdale Receipt of cancer screening procedures among Hispanic and non-Hispanic health maintenance organization members Cancer 91 2001 257 261
31. J.D. Hall, J.C. Boyd, M.C. Lippert, and D. Theodorescu Why patients choose prostatectomy or brachytherapy for localized prostate cancer: results of a descriptive survey Urology 61 2003 107 402
32. R.O. Roberts, E.J. Bergstralh, S.K. Katusic, M.M. Lieber, and S.J. Jacobsen Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota J. Urol. 161 1999 529 533
33. G. Bartsch, W. Horninger, and H. Klocker Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria Urology 58 2001 417 424
34. J.F. Bianco Jr., D.P. Wood Jr., D.J. Grignon, W.A. Sakr, J.E. Pontes, and I.J. Powell Prostate cancer stage shift has eliminated the gap in disease-free survival in black and white American men after radical prostatectomy J. Urol. 168 2002 479 482
35. J.H. Montie Staging of prostate cancer: current TNM classification and future prospects for prognostic factors Cancer 75 1995 1814 1818
36. C.B. Begg, E.R. Riedel, and P.B. Bach Variations in morbidity after radical prostatectomy N. Engl. J. Med. 346 2002 1138 1144
37. G. Lu-Yao, P.C. Albertsen, J.L. Stanford, T.A. Stukel, E.S. Walker-Corkery, and M.J. Barry Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut BMJ 325 2002 740 743
38. Centers for disease control and prevention State specific prevalence estimates of uninsured and underinsured persons - behavioral risk factor surveillance system, 1995 MMWR 47 1998 51 55
39. L. Perron, L. Moore, I. Bairati, P.M. Beranrd, and F. Meyer PSA screening and prostate cancer mortality CMAJ 166 2002 586 591
40. S.E. Oliver, D. Gunnell, and J.L. Donovan Comparison of trends in prostate-cancer mortality in England and Wales and the USA Lancet 355 2000 1788 1789